[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chung-Ang University Hosptial, Chung-Ang University College of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100618840","transcatheter-arterial-embolization-using-nexsphere-f-for-chronic-shoulder-pain-refractory-to-conservative-treatment-100618840",false,"NCT07336849","Transcatheter Arterial Embolization Using Nexsphere-F for Chronic Shoulder Pain Refractory to Conservative Treatment","A Single-center, Prospective, Open Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Transcatheter Arterial Embolization Using 'Nexsphere-F' in Patients With Adhesive Capsulitis of the Shoulder Joint Refractory to Conservative Treatment.","TAE-FROST","Inclusion Criteria:\n\n* Patients who have voluntarily signed a written informed consent form after receiving an explanation of the purpose, methods, and potential effects of the clinical trial\n\n  * Patients aged between 19 and 85 years\n\n    * Patients with pain persisting for more than 3 months in the affected area and with a history of receiving physical therapy, analgesics\u002Fanti-inflammatory medications, or local injection treatments\n\n      * Patients with a measured shoulder joint range of motion (ROM) of less than 90 degrees ⑤ Patients who agree not to receive any conservative treatment other than those permitted in this clinical trial (physical therapy, medication \\[NSAIDs, opioid analgesics, acetaminophen\\], intra-articular injections such as hyaluronic acid)\n\n        * Patients who are willing to comply with the treatment and procedures of the clinical trial and participate in all follow-up evaluations through hospital visits or telephone surveys\n\nExclusion Criteria:\n\n* Patients with a history of surgery on the shoulder joint targeted for the clinical trial prior to screening\n\n  * Patients suspected of having a full-thickness rotator cuff tear\n\n    * Patients with bleeding disorders or coagulopathies (e.g., idiopathic thrombocytopenic purpura, hemophilia, disseminated intravascular coagulation)\n\n      * Patients with advanced atherosclerosis or vasospasm in the arm vessels, or those expected to have such conditions\n\n        * Patients with a known hypersensitivity to gelatin\n\n          ⑥ Patients with a known hypersensitivity to contrast media\n\n          ⑦ Patients who are pregnant or breastfeeding\n\n          ⑧ Patients with a localized infection at the pain site\n\n          ⑨ Patients deemed inappropriate for participation by the investigator due to ethical concerns or potential impact on the clinical trial results","ALL","19 Years","85 Years",{"count":21,"type":22},44,"ESTIMATED","INTERVENTIONAL",[25],"NA","Evaluation of the efficacy and safety of transcatheter arterial embolization using 'Nexsphere-F' for pain relief in patients with adhesive capsulitis of the shoulder joint that does not respond to conservative treatment.\n\nThis study aims to investigate the efficacy and safety of transcatheter arterial embolization using embolic agents in patients with adhesive capsulitis of the shoulder joint. This is a single-center, prospective, open-label, randomized clinical trial.",[28,29,30],"Adhesive Capsulitis of the Shoulder","Frozen Shoulder","Shoulder Adhesive Capsulitis","RECRUITING","2026-05-18",{"date":34,"type":35},"2026-05-19","ACTUAL",{"date":37,"type":35},"2025-09-18",{"date":39,"type":22},"2027-08-31",{"name":41,"class":42},"Chung-Ang University Hosptial, Chung-Ang University College of Medicine","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100635998","NCT07559968","12-mm Partial Covered Versus Bare Self-Expandable Metallic Stents for Malignant Distal Biliary Obstruction","12-mm Partial Covered Versus Bare Self-Expandable Metallic Stents for Malignant Distal Biliary Obstruction: A Prospective, Randomized Clinical Study","PCSEMS-12","Inclusion Criteria:\n\n* Patients who voluntarily provide written informed consent after receiving sufficient explanation of the study purpose, methods, and potential benefits and risks\n* Adults aged 19 years or older\n* Patients diagnosed with unresectable malignant distal biliary obstruction based on imaging studies (CT, MRI, ERCP, etc.) or histologic confirmation\n* Patients who have already undergone percutaneous transhepatic biliary drainage (PTBD) according to the institutional clinical protocol and are scheduled for metallic stent placement through the existing PTBD tract\n\nExclusion Criteria:\n\n* Patients with a previous history of biliary metallic stent placement\n* Patients with upper biliary obstruction (hilar level or above)\n* Patients with other major biliary lesions in addition to malignant distal biliary obstruction\n* Patients for whom the investigator judges that study conduct or data collection would be markedly difficult",{"count":52,"type":22},60,[25],"Metallic stents are commonly used for biliary drainage in patients with unresectable malignant distal biliary obstruction. However, it is unclear whether a 12-mm partially covered self-expandable metallic stent or a 12-mm bare self-expandable metallic stent provides better effectiveness and safety. This prospective, randomized clinical trial will compare these two stent types in adult patients who have already undergone percutaneous transhepatic biliary drainage (PTBD) and are scheduled for metallic stent placement through the existing PTBD tract. A total of 60 participants will be enrolled. After stent placement, participants will be followed for 12 months, with assessments at 3, 6, and 12 months. The study will evaluate recurrent biliary obstruction, stent patency duration, reintervention, overall survival, and procedure-related complications. The results are expected to provide evidence for selecting the most appropriate 12-mm metallic stent for patients with unresectable malignant distal biliary obstruction.",[56,57,58],"Malignant Distal Biliary Obstruction","Malignant Biliary Obstruction","Biliary Obstruction",[60,61,62,63,64,65,66],"12-mm metallic stent","partially covered self-expandable metallic stent","bare self-expandable metallic stent","malignant distal biliary obstruction","PTBD","recurrent biliary obstruction","stent patency","NOT_YET_RECRUITING","2026-04-30",{"date":70,"type":35},"2026-05-06",{"date":72,"type":22},"2026-05",{"date":74,"type":22},"2029-12-31",{"name":41,"class":42},""]